集采逆袭，出海翻身：甘李药业完成一场漂亮的反杀！

Core Viewpoint - Ganli Pharmaceutical (603087.SH) is expected to achieve a net profit of 1.1 to 1.2 billion yuan in 2025, representing a year-on-year growth of 79% to 95%, driven by a significant recovery in its insulin business amidst procurement pressures [3][4]. Group 1: Core Business Growth - The growth of Ganli is primarily attributed to the substantial improvement in its domestic insulin business, with revenue increasing by 45.6% in the first three quarters of 2025, characterized by both volume and price increases [4][6]. - A key turning point was the successful participation in the 2024 national insulin procurement, where all six products were selected, leading to a more than 30% increase in procurement volume compared to the previous round [6]. - The company's gross margin has stabilized above 73% over the past two years, recovering from a significant drop post-2022 procurement, indicating effective cost control and product structure optimization [6][9]. Group 2: Market Position and Competition - Ganli's share of the third-generation insulin procurement volume has reached 30%, making it the leading domestic player, second only to Novo Nordisk, as foreign market shares decline [9]. - The company has expanded its product coverage to over 40,000 medical institutions, with rapid growth in grassroots markets [9]. Group 3: International Expansion - International sales revenue for Ganli reached 350 million yuan in the first three quarters of 2025, marking a 45.5% year-on-year increase [10]. - A significant breakthrough was a 10-year technical transfer and supply agreement with Brazil, valued at no less than 3 billion yuan, making Ganli the only approved solution for Brazil's national public health system [10][11]. - The company's strategy involves not just drug exports but also high-level "technology output," including local production technology transfer and talent training [11][12]. Group 4: Research and Development Focus - Ganli is heavily investing in research and development, with R&D expenses accounting for 13.4% of revenue in the first three quarters of 2025 [13]. - The company is targeting the next frontier in diabetes treatment with products like GZR4 (ultra-long-acting insulin) and GZR18 (GLP-1 dual-week formulation), both of which are in advanced clinical stages and have significant market potential [15][16]. - Ganli aims to transition from being an "insulin expert" to a "comprehensive solution provider for metabolic diseases" upon successful product launches [16].